General Biologicals Corporation (TPEX:4117)

Market Cap	739.02M -32.9%
Revenue (ttm)	251.38M +3.7%
Net Income	-243.60M
EPS	-4.07
Shares Out	60.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	89,677
Average Volume	282,797
Open	12.30
Previous Close	12.30
Day's Range	11.95 - 12.30
52-Week Range	11.40 - 24.90
Beta	0.56
RSI	44.35
Earnings Date	Apr 24, 2026

About General Biologicals

General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening services for hepatitis and HIV; and biomaterial, such as antibody biomaterials and human plasma. Additionally, it offers a range of oral care products...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1984
• Employees: 81
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4117

Financial Performance

In 2024, General Biologicals's revenue was 251.93 million, a decrease of -4.87% compared to the previous year's 264.83 million. Losses were -220.82 million, 11.1% more than in 2023.